In this episode, Dr Aleksandra Zuraw delves into the complex world of digital pathology reimbursement and aligning it with its value. She interviews our Chief Clinical and Regulatory Officer, Esther Abels, who played a key role in establishing a regulatory pathway for digital pathology. Esther highlights the significance of promoting an understanding of the health economic benefits and patient improvements.

Medical tests and procedures can get reimbursed based on Current Procedural Terminology (CPT) codes by the American Medical Association (AMA). But obtaining a code for digital pathology, which is more complex, requires a shift from fee-for-service to value-based reimbursement. To prove value, the services and added value must be defined, supported by relevant data, and linked to physician involvement and stakeholder values. For example, an AI-assisted metastasis detection application can save pathologists time and increase diagnostic consistency, leading to faster treatment and improved patient care. Digital pathology’s benefits can lead to reimbursement and better patient outcomes.

• Let us know what you think of the episode and any topics you would like us to cover in the future by sending us an email at: podcasts@visiopharm.com

Please note, Esther Abels no longer works at Visiopharm.

Analyzing slides for lymph node metastasis detection is tedious and time-consuming. What if you could automate your workload without sacrificing accuracy?

In this webinar Dr. Stine Harder and Dzenita Omanovic will introduce the first multi-indication AI-assisted, CE-IVD Metastasis Detection APP. Using data from two studies which compare the standard practice of assessing metastasis-status in lymph nodes by manual scoring with an AI-based image analysis approach for breast and colon carcinoma, they will showcase how this APP performs in a clinical setting.

Find out how you can use this APP to efficiently order, identify, and assess metastasis in lymph nodes.

• • How to improve your detection sensitivity of metastatic regions compared to current standards

• • How to save time with automated slide sorting to select the slides you want to review first

• • How to easily integrate this APP into your diagnostic workflow

Stine Harder, PhD, Head of Clinical Product Management, Visiopharm

Stine’s passion is image analysis and she continued her research during a 2-year postdoc tenure. She has a Ph.D. in Image Analysis from the Technical University of Denmark. In her current position, Stine oversees the complete lifecycle of Visiopharm’s clinical products

Dzenita Omanovic, Image Analysis Specialist, Visiopharm

Dzenita is highly skilled in CE-IVD apps and data sourcing and management. She specializes in external collaborations and projects of the clinical CE-IVD or future FDA scope.

Please note, Dzenita Omanovic no longer works at Visiopharm.